What is Mimetas?
Mimetas is a leader in the biotechnology sector, specializing in the development of advanced human tissue models that replicate complex human physiology. Their flagship OrganoPlate platform, alongside a suite of organoids and contract research organization (CRO) services, provides pharmaceutical researchers with actionable insights into drug efficacy and safety. By focusing on oncology, immunology, and metabolic diseases, Mimetas enables more reliable decision-making in the drug development pipeline. The company's commitment to ethical innovation is central to its value proposition, as it actively works to reduce reliance on animal testing while simultaneously delivering more reproducible and clinically relevant data for global pharmaceutical partners.
How much funding has Mimetas raised?
Mimetas has raised a total of $6.8M across 2 funding rounds:
Unspecified
$1.6M
Unspecified
$5.2M
Unspecified (2014): $1.6M, investors not publicly disclosed
Unspecified (2014): $5.2M led by Zeeuws InvesterinsFonds and Participatiemaatschappij Oost Nederland NV
Key Investors in Mimetas
Zeeuws InvesterinsFonds
A regional investment firm focused on providing smart capital and strategic support to entrepreneurs in the Zeeland region to foster sustainable business growth.
Participatiemaatschappij Oost Nederland NV
A public venture capital firm based in East Netherlands that specializes in supporting frontrunners in the life sciences, high-tech, and manufacturing sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Mimetas?
With this major strategic investment, Mimetas is poised to scale its operational capacity and expand its footprint in the global drug discovery market. The company will likely prioritize the enhancement of its OrganoPlate platform to support increasingly complex disease models, thereby solidifying its competitive advantage in the life sciences sector. Future growth strategies will likely involve deepening partnerships with major pharmaceutical firms and expanding its CRO service offerings to meet the rising demand for high-fidelity, human-centric testing solutions. As the industry shifts toward more predictive, non-animal models, Mimetas is strategically positioned to lead this transition, ensuring that its technological advancements continue to drive efficiency and safety in the pharmaceutical innovation lifecycle.
See full Mimetas company page
